Bristol-Myers Squibb Company
Combination of Anti-LAG-3 Antibodies and Anti-PD-1 Antibodies to Treat Tumors
Last updated:
Abstract:
Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
Status:
Application
Type:
Utility
Filling date:
28 Feb 2022
Issue date:
16 Jun 2022